Liver Fibrosis Progression and Mortality in Hepatitis B– and C–Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES

Butt, Adeel A.; Yan, Peng; Aslam, Samia; Abou‐Samra, Abdul‐Badi; Sherman, Kenneth E.; Shaikh, Obaid S.

doi:10.1093/cid/ciz1097

Cited by 10 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multivariable logistic regression analysis was used to generate odds ratios and 95% confidence intervals for factors associated with attainment of SVR. Variables were included based on their known association with HCV virologic response and our previous published studies that have used similar variables (Butt et al, 2019a;Butt et al, 2019b;Butt et al, 2019c).…”

Section: Discussionmentioning

confidence: 99%

“…We used the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) for the current study. ERCHIVES has been detailed in numerous previous publications (Butt et al, 2019a;Butt et al, 2019b;Butt et al, 2019c). Briefly, all Veterans in the Department of Veterans Affairs healthcare system (VA) who were diagnosed to have HCV based on an positive HCV antibody test are included in the cohort.…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES

Butt

Yan

Aslam

et al. 2020

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Background: There are scant data regarding hepatitis C (HCV) virologic response to directly acting antiviral agents (DAAs) in chronic hepatitis B (HBV) and HCV coinfected persons. HCV treatment response in those with spontaneously cleared HBV infection is unknown. Methods: All HCV infected persons treated with a DAA regimen in ERCHIVES were identified and categorized into HBV/HCV-coinfected (HBsAg, HBV DNA or both positive), HCV-monoinfected, and resolved HBV (isolated HBcAb+). SVR rates were determined and compared for all groups. Logistic regression model was used to determine factors associated with SVR. Results: Among 115 HCV/HBV-coinfected, 38,570 HCV-monoinfected persons, and 13,096 persons with resolved HBV, 31.6% of HCV/HBV-coinfected, 24.6% of HCV-monoinfected and 26.4% with resolved HBV had cirrhosis at baseline. SVR was achieved in 90.4% of HCV/HBV-coinfected, 83.4% of HCV-monoinfected and 84.5% of those with resolved HBV infection (P = 0.04 HCV/HBV vs. HCV monoinfected). In a logistic regression model, those with HCV/HBV were more likely to achieve SVR compared with HCV monoinfected (OR 2.25, 95% CI 1.17, 4.31). For HCV/HBV coinfected, the SVR rates dropped numerically with increasing severity of liver fibrosis (P-value non-significant). Factors associated with a lower likelihood of attaining SVR included cirrhosis at baseline (OR 0.85, 95% CI 0.80, 0.92), diabetes (OR 0.93, 95% CI 0.87, 0.99) and higher pre-treatment HCV RNA (OR 0.86, 95% CI 0.84, 0.87). Conclusion: HBV/HCV-coinfected persons have higher overall SVR rates with newer DAA regimens. Though not statistically significant, the virologic response is graded, with decreasing SVR rates with increasing degree of liver fibrosis as determined by the FIB-4 scores.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Populationmentioning

confidence: 99%

Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES

Butt

Yan

Aslam

et al. 2020

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…When the injury is removed, activated HSCs (myofibroblasts) are reduced through deactivation or apoptosis to slow down the fibrotic process and even lead to regression. Studies have shown that patients with chronic hepatitis B or chronic hepatitis C have reduced liver fibrosis after receiving antiviral therapy[ 74 ]. In addition, therapies such as antioxidants, renin–angiotensin system inhibitors, and traditional Chinese medicine[ 75 ] are also considered promising for treatment of liver fibrosis, although more clinical trials are needed to confirm their safety and efficacy.…”

Section: Potential Application Of Ncrnas For the Treatment Of Liver F...mentioning

confidence: 99%

Role of noncoding RNAs in liver fibrosis

Li¹,

Gong²,

Huang³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Liver fibrosis is a wound-healing response following chronic liver injury caused by hepatitis virus infection, obesity, or excessive alcohol. It is a dynamic and reversible process characterized by the activation of hepatic stellate cells and excess accumulation of extracellular matrix. Advanced fibrosis could lead to cirrhosis and even liver cancer, which has become a significant health burden worldwide. Many studies have revealed that noncoding RNAs (ncRNAs), including microRNAs, long noncoding RNAs and circular RNAs, are involved in the pathogenesis and development of liver fibrosis by regulating signaling pathways including transforming growth factor-β pathway, phosphatidylinositol 3-kinase/protein kinase B pathway, and Wnt/β-catenin pathway. NcRNAs in serum or exosomes have been reported to tentatively applied in the diagnosis and staging of liver fibrosis and combined with elastography to improve the accuracy of diagnosis. NcRNAs mimics, ncRNAs in mesenchymal stem cell-derived exosomes, and lipid nanoparticles-encapsulated ncRNAs have become promising therapeutic approaches for the treatment of liver fibrosis. In this review, we update the latest knowledge on ncRNAs in the pathogenesis and progression of liver fibrosis, and discuss the potentials and challenges to use these ncRNAs for diagnosis, staging and treatment of liver fibrosis. All these will help us to develop a comprehensive understanding of the role of ncRNAs in liver fibrosis.

show abstract

“…A recent study reported on whether the clearance of HCV by DAA could improve the clinical outcomes of co-infected patients [32]. For persons with baseline significant fibrosis, as indicated by a FIB-4 score of 1.46-3.25, cirrhosis incidence was 49.3/1000 patient-years among 151 HCV/HBV co-infected patients and 18.2 among HCV mono-infected patients (p = 0.03).…”

Section: Daa-based Therapymentioning

confidence: 99%

Hepatitis C Virus and Hepatitis B Virus Co-Infection

Shih¹,

Liu

2020

Viruses

View full text Add to dashboard Cite

Hepatitis C virus (HCV) and hepatitis B virus (HBV) co-infection can be encountered in either virus endemic countries. Co-infection can also be found in populations at risk of parenteral transmission. Previous studies demonstrated a high risk of liver disease progression in patients with HCV/HBV co-infection; thus, they should be treated aggressively. Previous evidence recommended therapy combining peginterferon (pegIFN) alfa and ribavirin for co-infected patients with positive HCV RNA. Recent trials further advise using direct-acting antivirals (DAAs) for the clearance of HCV in the co-infected patients. Reactivation of HBV has been observed in patients post-intervention, with higher risks and earlier onset in those having had HCV cured by DAA- versus pegIFN-based therapy. The mechanism of HBV reactivation is an interesting but unsolved puzzle. Our recent study revealed that in vitro HBV replication was suppressed by HCV co-infection; HBV suppression was attenuated when interferon signaling was blocked. In vivo, the HBV viremia, initially suppressed by the presence of HCV super-infection, rebounded following HCV clearance by DAA treatment and was accompanied by a reduced hepatic interferon response. In summary, major achievements in the treatment of HCV/HBV co-infection have been accomplished over the past 20 years. Future clinical trials should address measures to reduce or prevent HBV reactivation post HCV cure.

show abstract

Liver Fibrosis Progression and Mortality in Hepatitis B– and C–Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES

Cited by 10 publications

References 12 publications

Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES

Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES

Role of noncoding RNAs in liver fibrosis

Hepatitis C Virus and Hepatitis B Virus Co-Infection

Contact Info

Product

Resources

About